1.11
-0.08 (-6.72%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Cabaletta Bio, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 0.0 |
| 平均 | 1.13 |
|
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 4.17% |
| 机构持股比例 | 76.72% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Superstring Capital Management Lp | 31 Dec 2024 | 822,293 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 25.00 (Guggenheim, 2,152.25%) | 购买 |
| 25.00 (HC Wainwright & Co., 2,152.25%) | 购买 | |
| 中 | 17.50 (1,476.58%) | |
| 低 | 3.00 (Wells Fargo, 170.27%) | 保留 |
| 平均值 | 15.83 (1,326.13%) | |
| 总计 | 5 购买, 1 保留 | |
| 平均价格@调整类型 | 0.780 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Citigroup | 16 May 2025 | 13.00 (1,071.17%) | 购买 | 0.000 |
| Guggenheim | 16 May 2025 | 25.00 (2,152.25%) | 购买 | 0.000 |
| 15 May 2025 | 25.00 (2,152.25%) | 购买 | 0.000 | |
| HC Wainwright & Co. | 01 Apr 2025 | 25.00 (2,152.25%) | 购买 | 1.17 |
| Morgan Stanley | 01 Apr 2025 | 22.00 (1,881.98%) | 购买 | 1.17 |
| UBS | 01 Apr 2025 | 7.00 (530.63%) | 购买 | 1.17 |
| Wells Fargo | 01 Apr 2025 | 3.00 (170.27%) | 保留 | 1.17 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合